Basic Information
| LncRNA/CircRNA Name | CANT1 |
| Synonyms | CANT1, DBQD, DBQD1, SCAN-1, SCAN1, SHAPY |
| Region | GRCh38_17:78991717-79009867 |
| Ensemble | ENSG00000171302 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | uveal melanoma |
| ICD-0-3 | C69.9 |
| Methods | qPCR, RNAi, RNA-FISH, Cell migration and invasion assay etc. |
| Sample | cell lines (HDF, MUM2B, OCM1, OCM1A, OM431, SP6.5, and 293T) |
| Expression Pattern | down-regulated |
| Function Description | CANT1 significantly reduced tumor metastatic capacity and tumor formation, either in cell culture or in animals harboring tumor xenograft. Intriguingly, XIST lncRNA serves as a potential target of CANT1, and JPX or FTX lncRNA subsequently serves as a contextual hinge to activate a novel CANT1-JPX/FTX-XIST long non-coding (lncing) pathway in UM. Moreover, CANT1 triggers the expression of JPX and FTX by directly binding to their promoters and promoting H3K4 methylation. |
| Pubmed ID | 28330694 |
| Year | 2017 |
| Title | CANT1 lncRNA Triggers Efficient Therapeutic Efficacy by Correcting Aberrant lncing Cascade in Malignant Uveal Melanoma. |
External Links
| Links for CANT1 | GenBank HGNC NONCODE |
| Links for uveal melanoma | OMIM COSMIC |